An international commission made the case for focusing on body fat quantity and the illnesses people experience.

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

It’s not easy to become a taxi driver in London. Since 1865, to operate a taxi, drivers have had to pass what’s known as “the ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

This partnership marks a significant step in leveraging the power of AI to enhance clinical trial outcomes. Perceiv AI's AD-Px™ engine, known for its ability to forecast disease progression in ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

A new discovery in blood immune cells has put researchers one step closer to identifying a blood biomarker that would allow ...